YOCHAI BIRNBAUM to Purinergic P2Y Receptor Antagonists
This is a "connection" page, showing publications YOCHAI BIRNBAUM has written about Purinergic P2Y Receptor Antagonists.
Connection Strength
1.946
-
A Comprehensive Review of the Pleiotropic Effects of Ticagrelor. Cardiovasc Drugs Ther. 2024 Aug; 38(4):775-797.
Score: 0.800
-
Ticagrelor protects the heart against reperfusion injury and improves remodeling after myocardial infarction. Arterioscler Thromb Vasc Biol. 2015 Aug; 35(8):1805-14.
Score: 0.485
-
The Cost of Breaking Even: a Perspective on the Net Clinical Impact of Adding Aspirin to Antithrombotic Therapies in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Cardiovasc Drugs Ther. 2024 Jun; 38(3):605-619.
Score: 0.199
-
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay. Cardiovasc Drugs Ther. 2020 08; 34(4):443-461.
Score: 0.173
-
Size matters in STEMI: time for translation of ticagrelor? Cardiovasc Res. 2018 12 01; 114(14):1817-1818.
Score: 0.155
-
Ticagrelor and Rosuvastatin Have Additive Cardioprotective Effects via Adenosine. Cardiovasc Drugs Ther. 2016 Dec; 30(6):539-550.
Score: 0.135